Three Cancer Drugs Have Reached the Clinic: Inside GT Biopharma's TriKE Bet
A paid commentary by Biotech Insider highlights GT Biopharma's (GTBP) clinical progress, noting that three TriKE candidates have reached human testing. The article focuses on GTB-5550, a solid-tumor NK cell engager that dosed its first patient in May 2026, and GTB-3650, a second-generation AML/MDS candidate in Phase 1.
Key figures
- Gtb 3650 dose range
- 1.25 µg/kg/day to 100 µg/kg/day
- Gtb 3650 patient count
- 14
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.